FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution

Why It Matters

A one‑trial default could speed market entry and cut development costs, yet regulatory uncertainty may heighten financial risk for biotech firms and affect patient access.

Key Takeaways

• FDA defaults to one pivotal trial for new drug applications
• 66% of 2024 NMEs approved using a single trial
• Policy extends one‑trial approach to non‑oncology therapeutic areas
• Experts cite regulatory discretion and uncertainty as major concerns
• Biotechs may still run two trials to mitigate approval risk

Pulse Analysis

The FDA’s move to a one‑trial default reflects an evolution of a model that has long existed in oncology and rare‑disease spaces. Since the 1990s, sponsors have leveraged accelerated approval pathways that accept surrogate endpoints and often rely on a single well‑controlled study. By formalizing this approach across therapeutic areas, the agency signals a willingness to reduce the evidentiary burden, potentially shortening development timelines and lowering R&D expenditures for high‑risk, high‑reward indications.

For biotech investors and executives, the policy presents a double‑edged sword. On one hand, fewer required trials can translate into faster cash flow and lower capital burn, making early‑stage companies more attractive. On the other, the FDA’s retained discretion—especially for common diseases, complex mechanisms, or surrogate outcomes—means that the promise of a streamlined path is not guaranteed. Companies must weigh the fiduciary risk of committing to a single pivotal study against the possibility of a later request for additional data, a scenario that has already disrupted pipelines for firms like Capricor and Replimune.

The real test will be how quickly the FDA converts the NEJM announcement into concrete guidance. Clear statutory criteria, training for reviewers, and transparent decision‑making frameworks would provide the regulatory certainty that experts like Harpreet Singh deem essential for sustained innovation. Until such clarity emerges, a prudent strategy for most biotechs is to maintain a parallel second‑trial plan or seek early Type C meetings, ensuring that they can pivot if the agency exercises its discretionary authority.